Evolis FGF5 Inhibitor-Base Hair Loss Serums Released
added 27th May 2015
Australian company Advangen Limited has released the world’s first clinically-validated Fibroblast Growth Factor 5 (FGF5) inhibitor hair loss product in the form of their evolis serum range. They are designed to be used by men with Male Pattern Baldness and women with Female Pattern Hair Loss.
FGF5 is a protein in the body which controls hair growth and determines hair length. Inhibiting his protein has been seen to prolong the growth phase of the hair growth cycle in animal trials. Advangen, and its parent company Cellmid, have been studying how to use this genetic information and transfer it into a hair growth boosting, hair loss preventing product for the past 12 years, finally resulting in these new serums.
The manufacturers claim the formula, which is made up of botanical extracts, ‘May benefit in reducing hair loss, leading to the appearance of thicker hair’.
With one designed for men and one designed for women, these genetic hair loss serums are meant to be applied topically by spraying 3-4 pumps to the affected areas twice per day (morning and night). It is recommended that results should become noticeable after 16 weeks but on-going use is necessary to maintain any results achieved.
Independent product testing was carried out in New York by AMA Laboratories, INC. on 32 individuals aged 31-55 with mild to moderate genetic hair loss. The results found that 82% of these test subjects saw a reduction in their hair loss, 44.2% found that more hairs were growing than shedding, and photographic monitoring estimated a 143.3% increase in participants’ hair quality and volume.
Safety tests did not discover any adverse side effects during the 16 week study.
Whilst these results are significant and encouraging, this was a small scale trial and further research on a more wide-reaching basis is needed to determine the long-term efficacy of the evolis serums, whether as a hair growth booster or as a potential hair loss treatment.
There is currently no information available as to whether these serums can also be used in conjunction with minoxidil, the only medically-proven hair loss treatment licensed by the MHRA and FDA for the treatment of androgenic alopecia in both men and women.